Tesamorelin + Ipamorelin
This blend combines Tesamorelin, a modified GHRH(1–44) analogue, with Ipamorelin, a synthetic pentapeptide in the growth hormone secretagogue class.
Product Procurement
Research-use catalog items with clear ordering, product context, and documentation support.
Tesamorelin + Ipamorelin — 15mg
$99.95
Product estimate
- NET VIAL CONTENT
- 15mg
- CATEGORY
- Specialty Compounds
- SKU
- ALS-TESAIPA-15MG
In stock
Research Use Notice
For laboratory research use only. Not for human or animal use or consumption. Not for diagnostic, therapeutic, or veterinary use. Product documentation and certificates of analysis do not establish safety or suitability for these uses.
Product Intelligence
Tesamorelin + Ipamorelin Blend Profile
Tesamorelin and Ipamorelin research blend linking GHRH-analogue and growth hormone secretagogue research, with 15mg total vial content.
15mg Total Vial Content
Each vial contains 15mg combined total of Tesamorelin and Ipamorelin.
GHRH / Secretagogue Pathway Context
Tesamorelin literature examines a modified GHRH analogue through preclinical pharmacology and peptide-degradation studies. Ipamorelin literature uses pituitary-cell and receptor-antagonist experiments to characterize a distinct secretagogue pathway. Together, the individual component literature provides context for studying peptide structure, receptor selectivity, and endocrine-cell signaling. (Ferdinandi et al., 2007; PMID 17214611; Raun et al., 1998; PMID 9849822.)
- Product TypePeptide blend
- ComponentsTesamorelin; Ipamorelin
- Total Vial Content15mg
- IdentifierTesamorelin: PubChem CID 16137828; Ipamorelin: PubChem CID 9831659
Documentation
Verification & Documentation
Documentation is handled by product and lot. Use Standards to search for a matching record; if none appears, contact support with the product name, SKU, and lot number.